1.
Alimentary Pharmacology & Therapeutics
by Pounder, R.E.
Alimentary pharmacology & therapeutics, 2008, Vol.27 (1), p.1-1
2.
Letter: limb, muscle, and bone in coeliac disease in ALIMENTARY PHARMACOLOGY and THERAPEUTICS, vol 42, issue 11-12, pp 1332-1333
by Davie, M
Alimentary pharmacology & therapeutics, 2015, Vol.42 (11-12), p.1332
3.
Editors’ declarations of interest: Alimentary Pharmacology & Therapeutics
by Pounder, R. E.
Alimentary pharmacology & therapeutics, 2008, Vol.28 (1), p.1-1
4.
Alimentary Pharmacology & Therapeutics
by Pounder, R. E.
Alimentary pharmacology & therapeutics, 2007, Vol.25 (1), p.2-2
5.
Alimentary Pharmacology & Therapeutics
Alimentary pharmacology & therapeutics, 1999, Vol.13, p.no-no
6.
Alimentary Pharmacology & Therapeutics
Alimentary pharmacology & therapeutics, 1999, Vol.13, p.0-0
7.
Research supported by Alimentary Pharmacology & Therapeutics
Alimentary pharmacology & therapeutics, 1993, Vol.7 (1), p.2-3
8.
Referees for Alimentary Pharmacology & Therapeutics
Alimentary pharmacology & therapeutics, 1990, Vol.4 (6), p.659-659
9.
Funding source and conflict of interest disclosures by authors and editors in gastroenterology specialty journals revisited
by Qureshi, J.
Alimentary pharmacology & therapeutics, 2012, Vol.35 (6), p.690-695
10.
Introduction: thrombocytopenia in chronic liver disease – treatment implications and novel approaches
by AFDHAL, N.H.
Alimentary pharmacology & therapeutics, 2007, Vol.26 (s1), p.1-4
11.
PWE-151 Comparison Of Type 1 Autoimmune Hepatitis Patients’ Characteristic In Caucasian, Asian And Black Ethnic Groups: A Single Centre Experience
by Than, NN
Gut, 2014, Vol.63 (Suppl 1), p.A191-A191
12.
PWE-090 Outcomes of Patients with Ulcerative Colitis who are Azathioprine Tolerant and Azathioprine Intolerant
by Lee, L
Gut, 2013, Vol.62 (Suppl 1), p.A167
13.
Nine scoring models for short‐term mortality in alcoholic hepatitis: cross‐validation in a biopsy‐proven cohort
by Papastergiou, V.
Alimentary pharmacology & therapeutics, 2014, Vol.39 (7), p.721-732
14.
PWE-104 Vitamin D in Inflammatory Bowel Disease. A Semi-Qualitative Assessment of the Patient Experience
by Mohammad, M S
Gut, 2013, Vol.62 (Suppl 1), p.A172-A173
15.
Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori
by FISCHBACH, L.
Alimentary Pharmacology and Therapeutics, 2007, Vol.26 (3), p.343-357
16.
Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease
by Steenholdt, C.
Alimentary pharmacology & therapeutics, 2013, Vol.37 (12), p.1172-1183
17.
Randomised clinical trial: ghrelin agonist TZP‐101 relieves gastroparesis associated with severe nausea and vomiting – randomised clinical study subset data
by Wo, J. M.
Alimentary pharmacology & therapeutics, 2011, Vol.33 (6), p.679-688
18.
Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care:...
by GUYONNET, D.
Alimentary Pharmacology and Therapeutics, 2007, Vol.26 (3), p.475-486
19.
The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT‐1001 in coeliac disease subjects: a proof of concept study
by PATERSON, B. M.
Alimentary Pharmacology and Therapeutics, 2007, Vol.26 (5), p.757-766
20.
Medical and non‐medical predictors of initiating long‐term use of proton pump inhibitors: a nationwide cohort study of first‐time users during a 10‐year period
by Haastrup, P. F.
Alimentary pharmacology & therapeutics, 2016, Vol.44 (1), p.78-87
